Canaccord Genuity Reiterates a 'Buy' on AcelRx Pharmaceuticals (ACRX); Q3/11: ARX-01 on Track to Enter Phase 3 by Year End
Tweet
Share
E-mailGet Alerts ACRX Hot Sheet
Price: $0.86 --0%
Rating Summary:
10 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 18 | New: 11
Rating Summary:
10 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 18 | New: 11
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on AcelRx Pharmaceuticals (NASDAQ: ACRX) price target of $6.00.
Canaccord analyst, Ritu Baral, said, "Reiterate rating and price target on lead candidate ARX--01’s chance of success in patient controlled post--operative analgesia. ARX-01 is ACRx’s transmucosal sufentanil-based drug-device combotherapy for patient controlled post-operative analgesia. We think -01’s two upcoming Phase 3 trials (one vs. placebo, one vs. gold standard IV PCA comparator) will yield positive data mid-2012. AcelRx has a pipeline of drug-device combo pain relief therapies around its core NanoTab sulfentanil formulation."
For an analyst ratings summary and ratings history on AcelRx Pharmaceuticals click here. For more ratings news on AcelRx Pharmaceuticals click here.
Shares of AcelRx Pharmaceuticals closed at $2.88 yesterday.
Canaccord analyst, Ritu Baral, said, "Reiterate rating and price target on lead candidate ARX--01’s chance of success in patient controlled post--operative analgesia. ARX-01 is ACRx’s transmucosal sufentanil-based drug-device combotherapy for patient controlled post-operative analgesia. We think -01’s two upcoming Phase 3 trials (one vs. placebo, one vs. gold standard IV PCA comparator) will yield positive data mid-2012. AcelRx has a pipeline of drug-device combo pain relief therapies around its core NanoTab sulfentanil formulation."
For an analyst ratings summary and ratings history on AcelRx Pharmaceuticals click here. For more ratings news on AcelRx Pharmaceuticals click here.
Shares of AcelRx Pharmaceuticals closed at $2.88 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Downgrades Qifu Technology (QFIN) to Equalweight
- Tigress Financial Partners Starts Jersey Mike's Subs (JMKE) at Buy
- Macy's (M) PT Raised to $10 at UBS Following Channel Checks
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
